CONTENTS:
• Promoting smoking cessation through smoking reduction during Ramadan. Aveyard P., Begh R., Sheikh A., Amos A., p. 1379-1380.
• Addiction Research Centres and the Nurturing of Creativity The Norwegian Centre for Addiction Research (SERAF). Bramness J.G., Clausen T., Duckert F., Ravndal E., Waal H., p. 1381-1385.
• Conversation with Francesc Freixa. 1386-1390.
• Alcohol-related negative consequences among drinkers around the world. Graham K., Bernards S., Knibbe R., Kairouz S., Kuntsche S., Wilsnack S.C., et al., p. 1391-1405.
• A systematic and methodological review of interventions for young people experiencing alcohol-related harm. Calabria B., Shakeshaft A.P., Havard A., p. 1406-1418.
• Similar profile of cognitive impairment and recovery for Aboriginal Australians in treatment for episodic or chronic alcohol use. Dingwall K.M., Maruff P., Cairney S., p. 1419-1426.
• Gender differences in the impact of families on alcohol use: a lagged longitudinal study of early adolescents. Kelly A.B., O'Flaherty M., Toumbourou J.W., Connor J.P., Hemphill S.A., Catalano R.F., p. 1427-1436.
• Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan. Huang Y.F., Kuo H.S., Lew-Ting C.Y., Tian F., Yang C.H., Tsai T.I., et al., p. 1437-1445.
• Socio-economic determinants of drugged driving - a register-based study. Karjalainen K., Lintonen T., Impinen A., Lillsunde P., Makela P., Rahkonen O., et al., p. 1448-1459.
• The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Middleton L.S., Nuzzo P.A., Lofwall M.R., Moody D.E., Walsh S.L., p. 1460-1473.
• Methamphetamine users show greater than normal age-related cortical gray matter loss. Nakama H., Chang L., Fein G., Shimotsu R., Jiang C.S., Ernst T., p. 1474-1483.
• Hypothalamic-pituitary-adrenal axis reactivity to social stress and adolescent cannabis use: the TRAILS study. Prince van Leeuwen A., Creemers H.E., Greaves-Lord K., Verhulst F.C., Ormel J., Huizink A.C., p. 1484-1492.
• What impact have tobacco control policies, cigarette price and tobacco control programme funding had on Australian adolescents' smoking? Findings over a 15-year period. White V.M., Warne C.D., Spittal M.J., Durkin S., Purcell K., Wakefield M.A., p. 1493-1502.
• Plain packaging increases visual attention to health warnings on cigarette packs in non-smokers and weekly smokers but not daily smokers. Munafo M.R., Roberts N., Bauld L., Leonards U., p. 1505-1510.
• Prescribing of nicotine replacement therapy to adolescents in England. Langley T.E., Huang Y., Lewis S., McNeill A., Coleman T., Szatkowski L., p. 1513-1519.
• Social gradient in initiation and transition to daily use of tobacco and cannabis during adolescence: a retrospective cohort study. Legleye S., Janssen E., Beck F., Chau N., Khlat M., p. 1520-1531.
• Gordon Alan Marlatt (1941-2011). Roffman R.A., p. 1532-1533.
• Is it time to start discussing what type of computer-delivered intervention? Cunningham J.A., p. 1534.
• Treating addictions with deep brain stimulation is premature but well-controlled clinical trials should be performed. Vorspan F., Mallet L., Corvol J.C., Pelissolo A., Lepine J.P., p. 1535-1536.
• Deep brain stimulation for the treatment of addiction. Kuhn J., Moller M., Muller U., Bogerts B., Mann K., Grundler T.O., p. 1536-1537.
• Science, safety and costs make deep brain stimulation for addiction a low priority: a reply to Vorspan et al. (2011) and Kuhn et al. (2011). Hall W., Carter A., p. 1537-1538.